These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 7622225)

  • 1. Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization.
    Nakajima R; Motin VL; Brubaker RR
    Infect Immun; 1995 Aug; 63(8):3021-9. PubMed ID: 7622225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.
    Nakajima R; Brubaker RR
    Infect Immun; 1993 Jan; 61(1):23-31. PubMed ID: 8418045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Recombinant Attenuated
    Singh AK; Curtiss R; Sun W
    Infect Immun; 2019 Oct; 87(10):. PubMed ID: 31331960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.
    Motin VL; Nakajima R; Smirnov GB; Brubaker RR
    Infect Immun; 1994 Oct; 62(10):4192-201. PubMed ID: 7927675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
    Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
    Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.
    Noel BL; Lilo S; Capurso D; Hill J; Bliska JB
    Clin Vaccine Immunol; 2009 Oct; 16(10):1457-66. PubMed ID: 19710295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LcrV delivered via type III secretion system of live attenuated Yersinia pseudotuberculosis enhances immunogenicity against pneumonic plague.
    Sun W; Sanapala S; Henderson JC; Sam S; Olinzock J; Trent MS; Curtiss R
    Infect Immun; 2014 Oct; 82(10):4390-404. PubMed ID: 25114109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regions of Yersinia pestis V antigen that contribute to protection against plague identified by passive and active immunization.
    Hill J; Leary SE; Griffin KF; Williamson ED; Titball RW
    Infect Immun; 1997 Nov; 65(11):4476-82. PubMed ID: 9353022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine Potential of a Recombinant Bivalent Fusion Protein LcrV-HSP70 Against Plague and Yersiniosis.
    Gupta A; Narayan B; Kumar S; Verma SK
    Front Immunol; 2020; 11():988. PubMed ID: 32595634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNFα and IFNγ contribute to F1/LcrV-targeted immune defense in mouse models of fully virulent pneumonic plague.
    Lin JS; Park S; Adamovicz JJ; Hill J; Bliska JB; Cote CK; Perlin DS; Amemiya K; Smiley ST
    Vaccine; 2010 Dec; 29(2):357-62. PubMed ID: 20840834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in the lcrV gene of Yersinia enterocolitica and their effect on plague protective immunity.
    Miller NC; Quenee LE; Elli D; Ciletti NA; Schneewind O
    Infect Immun; 2012 Apr; 80(4):1572-82. PubMed ID: 22252870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral and cellular immune correlates of protection against bubonic plague by a live Yersinia pseudotuberculosis vaccine.
    Demeure CE; Derbise A; Guillas C; Gerke C; Cauchemez S; Carniel E; Pizarro-Cerdá J
    Vaccine; 2019 Jan; 37(1):123-129. PubMed ID: 30467064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Yersinia pestis V protein epitopes recognized by CD4 T cells.
    Parent MA; Berggren KN; Mullarky IK; Szaba FM; Kummer LW; Adamovicz JJ; Smiley ST
    Infect Immun; 2005 Apr; 73(4):2197-204. PubMed ID: 15784563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.
    Gallagher TB; Mellado-Sanchez G; Jorgensen AL; Moore S; Nataro JP; Pasetti MF; Baillie LW
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007644. PubMed ID: 31430284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral vaccination with live attenuated Yersinia pseudotuberculosis strains delivering a FliC180-LcrV fusion antigen confers protection against pulmonary Y. Pestis infection.
    Singh AK; Wang X; Sun W
    Vaccine; 2020 May; 38(21):3720-3728. PubMed ID: 32278523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of an F1/V fusion protein in attenuated Salmonella typhimurium and protection of mice against plague.
    Leary SE; Griffin KF; Garmory HS; Williamson ED; Titball RW
    Microb Pathog; 1997 Sep; 23(3):167-79. PubMed ID: 9281474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.
    Leary SE; Williamson ED; Griffin KF; Russell P; Eley SM; Titball RW
    Infect Immun; 1995 Aug; 63(8):2854-8. PubMed ID: 7622205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.
    Szaba FM; Kummer LW; Wilhelm LB; Lin JS; Parent MA; Montminy-Paquette SW; Lien E; Johnson LL; Smiley ST
    Infect Immun; 2009 Oct; 77(10):4295-304. PubMed ID: 19620344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective immunity against a lethal respiratory Yersinia pestis challenge induced by V antigen or the F1 capsular antigen incorporated into adenovirus capsid.
    Boyer JL; Sofer-Podesta C; Ang J; Hackett NR; Chiuchiolo MJ; Senina S; Perlin D; Crystal RG
    Hum Gene Ther; 2010 Jul; 21(7):891-901. PubMed ID: 20180652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and protective immunity against bubonic plague and pneumonic plague by immunization of mice with the recombinant V10 antigen, a variant of LcrV.
    DeBord KL; Anderson DM; Marketon MM; Overheim KA; DePaolo RW; Ciletti NA; Jabri B; Schneewind O
    Infect Immun; 2006 Aug; 74(8):4910-4. PubMed ID: 16861680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.